HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Inclusion Criteria: 1. 18 years of age or older, of either gender 2. Has a histologically or cytologically confirmed malignant disease 3. Naïve to cytotoxic chemotherapy 4. Scheduled to receive first course of moderate emetic risk anticancer agents 5. Predicted life expectancy of ≥ 3 months 6. Has a performance status (ECOG scale) of 0 to 1 7. Adequate organ function 8. female subjects of childbearing potential must have a negative blood pregnancy test within 72 hours before randomization; and must be non-lactating; 9. Able and willing to provide a written informed consent Exclusion Criteria: 1. Received or planned to receive total body irradiation, or radiation therapy to the abdomen, pelvis, Whole brain and spinal cord, head and neck , or chest within 7 days before randomization or within Days 1 to 8 of treatment 2. Scheduled to receive any moderate emetic risk anticancer agents from Day 1 to 6 3. Planned to receive treatment with a chemotherapy regimen including ordinary paclitaxel (with castor oil as solvent); 4. Medications with potential antiemetic efficacy within 2 days before randomization; 5. Began using opioids within 7 days prior to randomization or had a dose adjustment within the last 7 days. 6. Systemic corticosteroid therapy or sedative antihistamines within 7 days before randomization; 7. Use of palonosetron within 14 days before randomization; 8. Use of NK-1 receptor antagonists within 28 days before randomization; 9. Use of moderate to strong CYP3A4 inhibitors within 7 days before randomization; use of moderate to strong CYP3A4 inducers or specific CYP2D6 substrates within 28 days before randomization; 10. Vomiting and/or retching and nausea within 24 hours before randomization; 11. Subjects with symptomatic brain metastases, or with any symptoms suggestive of brain metastases or intracranial hypertension; 12. With uncontrolled serosal effusion; 13. Patients with serious cardiovascular diseases; 14. Concurrent uncontrolled hypertension before randomization; 15. Patients with active hepatitis B, active hepatitis C, acquired immunodeficiency syndrome (AIDS) or HIV test positive, and active syphilis test positive; 16. Concomitant diseases where dexamethasone is contraindicated; 17. The presence of severe or inadequately controlled diseases; 18. Known contraindications to NK-1 receptor antagonists, 5-HT3 receptor antagonists, or dexamethasone; 19. Participation in another clinical trial within 30 days prior to randomization (based on the use of study medication); 20. The presence of severe emotional or psychiatric disorders, as assessed by the investigator as unsuitable for participation in this study; 21. Subjects who, in the opinion of the investigator, have other conditions that make them inappropriate for participation in this study.